| scholarly article | Q13442814 |
| P50 | author | Angeles Rodriguez-Hernandez | Q79996664 |
| Francisco Javier Padillo Ruiz | Q98458160 | ||
| P2093 | author name string | Miguel A Gómez-Bravo | |
| Jordi Muntané | |||
| Francisco J Padillo | |||
| Victor M Victor | |||
| Elena Navarro-Villarán | |||
| María Negrete | |||
| Miryam Cadenas | |||
| Raquel Chapresto-Garzón | |||
| P2860 | cites work | Finishing the euchromatic sequence of the human genome | Q22122488 |
| Targeted therapy for hepatocellular carcinoma: novel agents on the horizon | Q27002288 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Comparison of Stain-Free gels with traditional immunoblot loading control methodology. | Q34296489 | ||
| Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. | Q35080145 | ||
| Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery | Q35872080 | ||
| Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib | Q35911679 | ||
| Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies. | Q36102839 | ||
| p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation | Q36291789 | ||
| Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. | Q36325357 | ||
| Genomics and signaling pathways in hepatocellular carcinoma. | Q36733952 | ||
| Biology of SNU cell lines | Q37447033 | ||
| Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition | Q37631288 | ||
| Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations | Q38533025 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma | Q38812372 | ||
| Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria | Q39055310 | ||
| Depletion of tristetraprolin in breast cancer cells increases interleukin-16 expression and promotes tumor infiltration with monocytes/macrophages | Q39225975 | ||
| Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines | Q39429442 | ||
| Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells | Q39472703 | ||
| Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. | Q39499156 | ||
| A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression | Q39583700 | ||
| Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells | Q39633968 | ||
| Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma | Q39727018 | ||
| Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma | Q39883398 | ||
| Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. | Q39996225 | ||
| Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis. | Q41760141 | ||
| Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells. | Q42105382 | ||
| Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism. | Q42108995 | ||
| OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53. | Q42362014 | ||
| Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. | Q43050082 | ||
| AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. | Q43184161 | ||
| Use of HuH6 and other human-derived hepatoma lines for the detection of genotoxins: a new hope for laboratory animals? | Q46245523 | ||
| Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis. | Q49334697 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. | Q53179931 | ||
| Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. | Q54362470 | ||
| Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 | ||
| A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells | Q59650961 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration | Q60949661 | ||
| Expression of p21 and p27 in hepatoma cell lines with different p53 gene profile | Q78147925 | ||
| Human hepatocyte culture | Q83830231 | ||
| Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells | Q90198643 | ||
| Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells | Q91075380 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 5 | |
| P921 | main subject | cell differentiation | Q210861 |
| liver cancer | Q623031 | ||
| P304 | page(s) | 339 | |
| P577 | publication date | 2020-05-07 | |
| P1433 | published in | Cell Death and Disease | Q2197222 |
| P1476 | title | Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells | |
| P478 | volume | 11 |
Search more.